MedTrace Logo

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

NCT04173338 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-06-14

No results posted yet for this study

Summary

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

Conditions

  • Non Small Cell Lung Cancer
  • Non-squamous Non-small-cell Lung Cancer
  • Urothelial Carcinoma
  • Malignant Mesothelioma

Interventions

DRUG

Cabozantinib

start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.

DRUG

Pemetrexed

Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.

Sponsors & Collaborators

  • Augusta University

    lead OTHER

Principal Investigators

  • Nagla A Karim, MD, PhD · Augusta University Georgia Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-23
Primary Completion
2022-03-28
Completion
2022-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04173338 on ClinicalTrials.gov